ArticleHealth science reports2026
Combined Use of Botulinum Toxin A and Profhilo for Upper Face Rejuvenation: A Randomized Clinical Trial.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Interpretation Challenges in Combined Botulinum Toxin A and Profhilo Therapy: Letter to the Editor.Health science reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hyaluronic acid (HA) and Botulinum toxin A (BTX-A) treatments are highly regarded for their effectiveness in facial rejuvenation. Aim: To investigate whether adding Profhilo enhances the effects of BTX-A for frontal skin rejuvenation. Method: In a prospective clinical trial, 10 subjects were treated by upper face Profhilo plus Botulinum toxin A injection, and 10 age- and sex-matched controls received only Botulinum toxin A injection. Clinical and sonographic improvement were compared 3 months after the last treatment session. Results: A total of 20 participants (10 patients in each group), including 8 males (80%) and 2 females (20%) in the case group and 7 males (70%) and 3 females (30%) in the control group, were enrolled in the study. According to Merz scores before and 3 months after treatment, the wrinkles were dramatically reduced in both groups ( Conclusion: We have shown that adding Profhilo to BTX-A injection does not have any short-term clinical or sonographic advantage in frontal area wrinkle reduction. Further prospective studies with a longer follow-up period are warranted to evaluate any potential long-term effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.